Healthcare & Insurance
Integra LifeSciences Reports First Quarter 2019 Financial Results
Reported revenues amounted to $359.7 million; organic revenues increased 3.1% GAAP and adjusted earnings per diluted share were $0.38 and $0.65, respectively The Company reaffirms reported and organic revenue guidance for the full-year 2019 PLAINSBORO, N.J., April 24, 2019 (GLOBE NEWSWIRE)
Wednesday, April 24, 2019
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019
BEDMINSTER, N.J. and DUBLIN, Ireland, April 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the
Wednesday, April 24, 2019
Interim report for the first 3 months of 2019
Please read the full announcement in the attached PDF Attachment 2019_07_Q12019_CompanyAnnouncement_EN_FINAL
Wednesday, April 24, 2019
Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME,
Leuven, Belgium, 24 April 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it has completed enrollment of its Phase 1 study of THR-149, a novel plasma kallikrein
Wednesday, April 24, 2019
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines: Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all
Wednesday, April 24, 2019
MDxHealth (R): MDxHealth provides Q1 2019 business update
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - April
Wednesday, April 24, 2019
Number of shares and voting rights of Innate Pharma as at April 18, 2019
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT APRIL 18, 2019 Marseille, France, April 24, 2018, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers,
Wednesday, April 24, 2019
Pixium Vision and research partners to report clinical progress with the PRIMA bionic vision system during ARVO 2019 World Conference
Paris, April 24th, 2019 – 7:00 CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announced two presentations of interim clinical results with the
Wednesday, April 24, 2019
China FDA Approval for Oscar 2 Blood Pressure Monitor with CardieX’s "SphygmoCor® Inside" Technology
SYDNEY, Australia, April 23, 2019 (GLOBE NEWSWIRE) -- CardieX Limited (Australian Stock Exchange listed: CDX) announces approval by the Chinese Food and Drug Administration (CFDA) of the Oscar 2 with “SphygmoCor® Inside” Ambulatory Blood Pressure Monitor (ABPM), a product collaboration
Wednesday, April 24, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
LA JOLLA, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent
Tuesday, April 23, 2019
Psychemedics Announces First Quarter Results and Declares 91st Consecutive Quarterly Dividend
ACTON, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of May 7, 2019, to
Tuesday, April 23, 2019
Harvard Bioscience Schedules First Quarter 2019 Conference Call for May 2 at 4:30 PM ET
HOLLISTON, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2019 after market trading hours on Thursday, May 2, 2019.
Tuesday, April 23, 2019
Retrophin to Report First Quarter 2019 Financial Results
SAN DIEGO, April 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
Tuesday, April 23, 2019
ReWalk Robotics to Present at the ThinkEquity Conference on May 2nd
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 23, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer and Andy Dolan, Vice President of Marketing, will present at the ThinkEquity
Tuesday, April 23, 2019
Stryker reports first quarter 2019 operating results
Kalamazoo, Michigan, April 23, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2019: First Quarter Highlights Reported net sales increased 8.5% to $3.5 billionOrganic net sales increased 7.3%Reported operating income margin of
Tuesday, April 23, 2019
Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tuesday, May 7, 2019.
Tuesday, April 23, 2019
Diversicare to Announce First Quarter 2019 Financial Results on Thursday, May 2, 2019
BRENTWOOD, Tenn., April 23, 2019 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ:DVCR) today announced that it is scheduled to report financial results for its first quarter ended March 31, 2019, on Thursday, May 2, 2019, after the market closes. Diversicare will also hold a
Tuesday, April 23, 2019
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma AG (SIX: NOVN-CH) announced today the initiation of GECKO, a Phase 2 study testing a
Tuesday, April 23, 2019
Merit Medical Reports Earnings for Quarter Ended March 31, 2019
Q1 2019 worldwide revenue of $238.3 million, up 17.4% as reported over Q1 2018Q1 2019 core revenue on a comparable, constant currency basis* up 10.0% over Q1 2018Q1 2019 GAAP EPS was $0.11, compared to $0.10 in Q1 2018Q1 2019 non-GAAP EPS* was $0.37, compared to $0.31 in Q1 2018 * Core revenue
Tuesday, April 23, 2019
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trialPivotal clinical trial for pediatric
Tuesday, April 23, 2019
